PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors
    Marco-Benedi, Victoria
    Jarauta, Estibaliz
    Perez-Calahorra, Sofia
    Bea, Ana M.
    Civeira, Fernando
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2019, 31 (02): : 89 - 92
  • [22] Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs
    Zuin, Marco
    Corsini, Alberto
    Dalla Valle, Chiara
    De Rosa, Catia
    Maloberti, Alessandro
    Mojoli, Marco
    Rizzo, Massimiliano
    Ciccirillo, Francesco
    Madrid, Alfredo
    Riccio, Carmine
    Grimaldi, Massimo
    Colivicchi, Furio
    Oliva, Fabrizio
    Temporelli, Pier Luigi
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, : 719 - 724
  • [23] Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
    Karagiannis, Angelos D.
    Liu, Martin
    Toth, Peter P.
    Zhao, Shijia
    Agrawal, Devendra K.
    Libby, Peter
    Chatzizisis, Yiannis S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2018, 20 (04)
  • [24] PCSK9 Inhibition: From Current Advances to Evolving Future
    Liu, Chunping
    Chen, Jing
    Chen, Huiqi
    Zhang, Tong
    He, Dongyue
    Luo, Qiyuan
    Chi, Jiaxin
    Hong, Zebin
    Liao, Yizhong
    Zhang, Shihui
    Wu, Qizhe
    Cen, Huan
    Chen, Guangzhong
    Li, Jinxin
    Wang, Lei
    CELLS, 2022, 11 (19)
  • [25] The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
    Theocharidou, Eleni
    Papademetriou, Marianna
    Reklou, Andromachi
    Sachinidis, Alexandros
    Boutari, Chrisoula
    Giouleme, Olga
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3654 - 3657
  • [26] Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
    Smith, Alex
    Johnson, Drew
    Banks, Joshua
    Keith, Scott W.
    Karalis, Dean G.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [27] A LASSO-derived model for the prediction of nonattainment of target LDL-C reduction with PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease
    Duan, Xiaochun
    Zhang, Mengdi
    Sun, Xiaodong
    Lin, Yang
    Peng, Wenxing
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [28] PCSK9 inhibitors: current status and emerging frontiers in lipid control
    Agnello, Federica
    Mauro, Maria Sara
    Rochira, Carla
    Landolina, Davide
    Finocchiaro, Simone
    Greco, Antonio
    Ammirabile, Nicola
    Raffo, Carmelo
    Mazzone, Placido Maria
    Spagnolo, Marco
    Occhipinti, Giovanni
    Imbesi, Antonino
    Giacoppo, Daniele
    Capodanno, Davide
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2024, 22 (1-3) : 41 - 58
  • [29] PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
    Rashid, Hashrul
    Meredith, Ian T.
    Nasis, Arthur
    HEART LUNG AND CIRCULATION, 2017, 26 (08) : 786 - 798
  • [30] PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
    Blokhina, A., V
    Ershova, A., I
    Limonova, A. S.
    Kopylova, O., V
    Meshkov, A. N.
    Drapkina, O. M.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (06) : 808 - 815
12345